Literature DB >> 18215140

The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.

Magdalini Rapti1, Susan J Atkinson, Meng-Huee Lee, Andrew Trim, Marcia Moss, Gillian Murphy.   

Abstract

ADAM (a disintegrin and metalloproteinase) 10 is a key member of the ADAM family of disintegrin and metalloproteinases which process membrane-associated proteins to soluble forms in a process known as 'shedding'. Among the major targets of ADAM10 are Notch, EphrinA2 and CD44. In many cell-based studies of shedding, the activity of ADAM10 appears to overlap with that of ADAM17, which has a similar active-site topology relative to the other proteolytically active ADAMs. The tissue inhibitors of metalloproteinases, TIMPs, have proved useful in the study of ADAM function, since TIMP-1 inhibits ADAM10, but not ADAM17; however, both enzymes are inhibited by TIMP-3. In the present study, we show that, in comparison with ADAM17 and the MMPs (matrix metalloproteinases), the N-terminal domains of TIMPs alone are insufficient for the inhibition of ADAM10. This knowledge could form the basis for the design of directed inhibitors against different metalloproteinases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18215140     DOI: 10.1042/BJ20071430

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  18 in total

1.  Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2).

Authors:  Marie Kveiborg; Jonas Jacobsen; Meng-Huee Lee; Hideaki Nagase; Ulla M Wewer; Gillian Murphy
Journal:  Biochem J       Date:  2010-08-15       Impact factor: 3.857

Review 2.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.

Authors:  Keith Brew; Hideaki Nagase
Journal:  Biochim Biophys Acta       Date:  2010-01-15

3.  Role of ADAMs in endothelial cell permeability: cadherin shedding and leukocyte rolling.

Authors:  Bharathy Ponnuchamy; Raouf A Khalil
Journal:  Circ Res       Date:  2008-05-23       Impact factor: 17.367

4.  Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.

Authors:  Albert G Remacle; Sergey A Shiryaev; Ilian A Radichev; Dmitri V Rozanov; Boguslaw Stec; Alex Y Strongin
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

5.  Entropy increases from different sources support the high-affinity binding of the N-terminal inhibitory domains of tissue inhibitors of metalloproteinases to the catalytic domains of matrix metalloproteinases-1 and -3.

Authors:  Ying Wu; Shuo Wei; Steven R Van Doren; Keith Brew
Journal:  J Biol Chem       Date:  2011-03-28       Impact factor: 5.157

Review 6.  A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease.

Authors:  Sheng Zhong; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2019-03-21       Impact factor: 5.858

Review 7.  Disintegrin and Metalloproteinases (ADAMs [A Disintegrin and Metalloproteinase] and ADAMTSs [ADAMs With a Thrombospondin Motif]) in Aortic Aneurysm.

Authors:  Tolga Kilic; Keisuke Okuno; Satoru Eguchi; Zamaneh Kassiri
Journal:  Hypertension       Date:  2022-05-11       Impact factor: 9.897

Review 8.  Extracellular matrix turnover and outflow resistance.

Authors:  Kate E Keller; Mini Aga; John M Bradley; Mary J Kelley; Ted S Acott
Journal:  Exp Eye Res       Date:  2008-12-06       Impact factor: 3.467

9.  The C-terminal domains of ADAMTS-4 and ADAMTS-5 promote association with N-TIMP-3.

Authors:  Linda Troeberg; Kazunari Fushimi; Simone D Scilabra; Hiroyuki Nakamura; Vincent Dive; Ida B Thøgersen; Jan J Enghild; Hideaki Nagase
Journal:  Matrix Biol       Date:  2009-07-28       Impact factor: 11.583

10.  The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?

Authors:  Michael J Duffy; Maeve Mullooly; Norma O'Donovan; Sumainizah Sukor; John Crown; Aisling Pierce; Patricia M McGowan
Journal:  Clin Proteomics       Date:  2011-06-09       Impact factor: 3.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.